Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Castle Biosciences, Inc. (CSTL : NSDQ)

• Company Description    Castle Biosciences Inc. is a commercial-stage dermatological cancer company. It is focused on providing physicians and patients, clinically actionable genomic information. Castle Biosciences Inc. is based in Texas, United States. Number of Employees: 883

• Price / Volume Information    Yesterday's Closing Price: $20.15 Daily Weekly Monthly 20 Day Moving Average: 519,195 shares Shares Outstanding: 30.33 (millions) Market Capitalization: $611.15 (millions) Beta: 1.11 52 Week High: $44.28 52 Week Low: $14.59 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -14.94% -19.10% 12 Week -36.79% -41.57% Year To Date -48.20% -51.45%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 1500 W. Parkwood Ave Suite 400 - Friendswood,TX 77546 USA ph: 866-788-9007 fax: - ir@castlebiosciences.com https://castlebiosciences.com

• General Corporate Information    Officers Derek J. Maetzold - President and Chief Executive Officer Daniel M. Bradbury - Chairperson of the Board of Directors Frank Stokes - Chief Financial Officer Daniel M. Bradbury - Director Kimberlee S. Caple - Director Peer Information Castle Biosciences, Inc. (CORR.) Castle Biosciences, Inc. (RSPI) Castle Biosciences, Inc. (CGXP) Castle Biosciences, Inc. (BGEN) Castle Biosciences, Inc. (GTBP) Castle Biosciences, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 14843C105 SIC: 8071 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/26 Next Expected EPS Date: 08/03/26 Share - Related Items Shares Outstanding: 30.33 Most Recent Split Date: (:1) Beta: 1.11 Market Capitalization: $611.15 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.38 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-1.40 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/03/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 1.32 Price/Cash Flow: 18.10 Price / Sales: 1.80 EPS Growth vs. Year Ago Period: -145.00% vs. Previous Quarter: -512.50% Sales Growth vs. Year Ago Period: -4.90% vs. Previous Quarter: -3.83% ROE 03/31/26 - -2.77 12/31/25 - -0.89 09/30/25 - 1.73 ROA 03/31/26 - -2.30 12/31/25 - -0.74 09/30/25 - 1.47 Current Ratio 03/31/26 - 6.75 12/31/25 - 5.26 09/30/25 - 6.47 Quick Ratio 03/31/26 - 6.53 12/31/25 - 5.11 09/30/25 - 6.31 Operating Margin 03/31/26 - -3.78 12/31/25 - -1.18 09/30/25 - 2.29 Net Margin 03/31/26 - -3.78 12/31/25 - -7.02 09/30/25 - -3.56 Pre-Tax Margin 03/31/26 - -5.19 12/31/25 - -8.57 09/30/25 - -5.51 Book Value 03/31/26 - 15.21 12/31/25 - 16.13 09/30/25 - 16.00 Inventory Turnover 03/31/26 - 7.97 12/31/25 - 8.33 09/30/25 - 8.61 Debt-to-Equity 03/31/26 - 0.02 12/31/25 - 0.02 09/30/25 - 0.02 Debt-to-Capital 03/31/26 - 1.85 12/31/25 - 2.07 09/30/25 - 2.18

Powered by Zacks Investment Research ©